Cleveland BioLabs, Inc. (CBLI)
Q2 2012 Earnings Call
August 6, 2012, 10:30 a.m. ET
Rachel Levine – Director of IR & Communications
Yakov Kogan – CEO
C. Neil Lyons – CFO
Andrei Gudkov – CSO
Michael Fonstein – President
Michael Kurman – CMO
Ann Hards – EVP of Regulatory Affairs & QA
Walter Schenker - MAZ Partners
Chris Marai – Wedbush Securities
Robert Brous - Wunderlich Securities
Marty Meyerson - MH Meyerson & Company
Prashant Mehta - Netgain Financial
Bernie Brown – Private Investor
Greetings, and welcome to the Cleveland BioLabs Second Quarter 2012 Earnings
conference call. At this time, all participants are in a listen-only mode. A brief
question-and-answer session will follow the formal presentation. (Operator Instructions).
As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Ms. Rachel Levine, Director of Investor Relations and Communications for Cleveland BioLabs.
Thank you, Ms. Levine. You may begin.
Thank you, and good morning, everyone. Welcome to Cleveland BioLabs’ Second
Quarter 2012 Investor conference call. Joining us today are Dr. Yakov Kogan, Chief Executive Officer; Dr. Andrei Gudkov, Chief Scientific Officer; Dr. Michael Fonstein, President; Neil Lyons, Chief Financial Officer; Dr. Michael Kurman, Chief Medical Officer; Dr. Ann Hards, Executive Vice President of Regulatory Affairs and Quality Assurance
Before we begin, I would like to remind all listeners that throughout this call, we may
make statements that constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Investors are cautioned that any
such forward-looking statements are not guarantees of future performance or the